Cefazolin injection reduces the rate of postoperative endophthalmitis

Article

Administering cezafolin injections after cataract surgery reduces the rate of postoperative endophthalmitis.

Administering cefazolin injections after cataract surgery reduces the rate of postoperative endophthalmitis, claims a study in the journal Bio Med Central.

Dr Pedro Romero-Aroca et al., Ophthalmology Service. Hospital Universitari Sant Joan, IISPV, Universidad Rovira i Virgili, Reus, Spain, conducted a prospective, observational study on 25001 patients.

All participants were divided into two groups: Group 1, consisting of 11696 patients, was operated on between January 2002 and December 2002 and Group 2, with 13305 patients, was administered a 1 mg/0.1 bolus of intracameral cefazolin between January 2003 and December 2009.

Of the patients studied, there were 76 cases of endophthalmitis in Group 1, compared to 7 in Group 2. Postoperative endophthalmitis rate decreased from 0.63% to 0.05% after a cefazolin. The relative risk of endophthalmitis in Group 1, compared to Group 2, was 11.45.

Intracameral bolus injections of cefazolin after cataract surgery significantly reduce the rate of postoperative endophthalmitis.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.